Detailed results for the six patients with cardiac sarcoidosis (CS) in the normal group
| No. | Sex | Age years | Involved organ(s) except for heart | 18F-FDG PET | Cardiac MRI | ACE IU L−1 | Comments | Follow-up timings of PET and MRI | Outcome |
| 1 | F | 51 | LN#, skin# | FDG uptake in the RV papillary muscle | LGE in the RV papillary muscle | 21.4 | Small cardiac lesion in the RV | 6 M, 12 M, 24 M, 42 M | Natural remission after 3.5 years; FDG uptake disappeared and LGE remained at 42 M |
| 2 | F | 22 | Eye, LN#, lung# | FDG uptake in the mid-segment of the lateral wall of the LV | LGE in the mid-segment of the lateral (epicardial and endocardial layers) wall of the LV | 28.9 | Small cardiac lesion in the lateral wall of the LV | 6 M | Natural remission after 6 M; FDG uptake disappeared and LGE remained at 6 M |
| 3 | M | 35 | Bone, LN, skin#, stomach# | FDG uptake in the basal to mid-segments of the anteroseptal walls of the LV | LGE in the basal to mid-segment of the anteroseptal walls (subepicardial layer) of the LV | 23.5 | Multiorgan involvement (bone, LN, skin, stomach and heart) | 1 M, 6 M | Syncope with transient 2nd degree AVB and initiate steroid therapy. AVB improved; FDG uptake disappeared and LGE remained at 1 M and 6 M |
| 4 | F | 71 | Eye, LN#, lung | FDG uptake in the basal segments of the anterolateral and inferoseptal walls of the LV | LGE in the basal segment of the anterolateral (subepicardial layer) and inferoseptal walls (mid-layer) of the LV | 14.9 | Small cardiac lesions in the anterolateral and inferoseptal walls of the LV | 24 M | Natural remission after 24 M; FDG uptake disappeared and LGE remained at 24 M |
| 5 | F | 25 | Eye, LN#, lung, spleen | FDG uptake in the mid to apical segments of the anteroseptal and inferior walls | LGE in the mid-segments of the anteroseptal (subendocardial layer) and inferior walls (subepicardial layer) | 18.4 | Multiorgan involvement (eye, LN, lung, spleen and heart) | 3 M, 4 M | Follow-up after 3 M revealed progression of active cardiac and extracardiac involvements; degree and extent of FDG uptake and LGE enhanced at 3 M. Start steroid therapy. FDG uptake reduced and LGE remained at 4 M |
| 6 | M | 35 | LN, lung# | FDG uptake in the basal to mid-segments of the anterior wall and mid to apical segments of the septum | LGE in the basal to mid-segments of the anterior to anterolateral walls (subepicardial layer) and mid-segment of the septum (RV side) | 7.9 | Mildly reduced LVEF (49%) | 1 M, 3 M, 12 M | Start steroid therapy to preserve LVEF; no FDG uptake and LGE remained at 1 M, 3 M and 12 M; LVEF recovered to the normal range |
FDG: 18F-fluorodeoxy glucose; PET: positron emission tomography; MRI: magnetic resonance imaging; ACE: angiotensin-converting-enzyme; M: months; LN: lymph nodes; LV: left ventricle; RV: right ventricle; LGE: late gadolinium enhancement; AVB: atrioventricular block; LVEF: left ventricular ejection fraction. #: organ with diagnostic histology consistent with sarcoidosis.